

Cécile Blein^a, Francesca Barion^a, Olga Ostrovskaya^a, Tharun Balaji Suthagar^b, Vasanth Radhakrishnan^b, Rucha Kulkarni^c, Amit Goyal^d, Glenn Phillips^a ^aargenx BVBA, Industriepark Zwijnaarde 7, Ghent, Belgium; ^bZS Associates, Bengaluru, Karnataka, India; ^cZS Associates, Two Bethesda Metro Center, Bethesda, MD, USA; ^dZS Associates, 210 Carnegie Center, Princeton, NJ, USA.

Introduction and Purpose

- Pemphigus foliaceus (PF) is an autoimmune blistering disease of the skin characterized by multiple, pruritic, scaly, cutaneous erosions and flaky patches primarily appearing on the face, scalp, trunk and extremities.^{1,2}
- Although rare worldwide, with <50,000 individuals in the United States</p> (US)² diagnosed with PF, it was lethal in almost 60% of patients prior to the implementation of corticosteroid (CS) therapy.³
- Current first-line treatment options for PF include CS, immunosuppressants (IS), and rituximab. Other treatment options, used alone or in combination, include broad-spectrum antibiotics and immunoglobulins.^{4,5}
- Better understanding of real-world treatment patterns in PF is critical to identify any subpopulations with pronounced burden or unmet need. Therefore, this study aimed to (1) descriptively analyze the characteristics of patients with PF, and (2) evaluate their PF treatment utilization, using a US claims database.

Methods

The Komodo Health closed claims database (January 2015-December 2022), containing complete medical and prescription claims information from >150 payers across all geographic regions of the US, was utilized for the analysis. The details of the study design are provided in **Figure 1**.

Figure 1. Study design

	1 st PF diagn	osis claim (Index dat	e) 2 nd Pl	F claim (30–365	days from 1	st diagnosis)
Years				No more t exclusionary c		
2018		2019	2020		2021	2
		Pa	tient selection w	vindow	~	
	_		_	-		
Key pati	ent selec	tion criteria				
			10 9 [pemphigus	1) diagnosis >3() to <365 day	(s anart
• ≥2 claims	with PF (ICD	codes L10.2 [PF] or L				-
 ≥2 claims with the 2 	with PF (ICD (L st claim captu	codes L10.2 [PF] or L ured between Januar				-
 ≥2 claims with the 2 Patients a 	with PF (ICD L st claim captu ged ≥18 years	codes L10.2 [PF] or L ured between Januar s at index	y 2019 and Dece			-
 ≥2 claims with the 1 Patients a Continuo 	with PF (ICD L st claim captu ged ≥18 years us enrollment	codes L10.2 [PF] or L ured between Januar s at index t ± 1-year pre- and po	y 2019 and Dece ost-index date	mber 2021 (firs	st considered	index date)
 ≥2 claims with the 3 Patients a Continuo Patients v 	with PF (ICD) L st claim captu ged ≥18 years us enrollment vith no more	codes L10.2 [PF] or L ured between Januar s at index t ± 1-year pre- and po than 1 exclusionary o	y 2019 and Dece ost-index date diagnosis ^a for PF	mber 2021 (firs for 1-year after	their 2 nd dia	index date) gnoses
 ≥2 claims with the 2 Patients a Continuo Patients v ^aExclusionary 	with PF (ICD) L st claim captu ged ≥18 years us enrollment vith no more s diagnosis refers t	codes L10.2 [PF] or L ured between Januar s at index t ± 1-year pre- and po	y 2019 and Dece ost-index date liagnosis ^a for PF ndition reached by a p	for 1-year after	their 2 nd dia	index date) gnoses
 ≥2 claims with the 2 Patients a Continuo Patients v ^aExclusionary cannot be es 	with PF (ICD of L st claim captu ged ≥18 years us enrollment with no more of diagnosis refers t tablished with cor	codes L10.2 [PF] or L ured between Januar is at index t ± 1-year pre- and po than 1 exclusionary o to diagnosis of a medical co	y 2019 and Dece ost-index date liagnosis ^a for PF ndition reached by a p	for 1-year after	their 2 nd dia	index date) gnoses
 ≥2 claims with the 2 Patients a Continuo Patients v ^aExclusionary 	with PF (ICD of L st claim captu ged ≥18 years us enrollment with no more of diagnosis refers t tablished with cor	codes L10.2 [PF] or L ured between Januar is at index t ± 1-year pre- and po than 1 exclusionary o to diagnosis of a medical co	y 2019 and Dece ost-index date liagnosis ^a for PF ndition reached by a p	for 1-year after	their 2 nd dia	index date) gnoses
 ≥2 claims with the 2 with the 2 Patients a Continuo Patients was a continuo Patients was a continuo be estimated by a continuo be continuo be es	with PF (ICD of L st claim captu ged ≥18 years us enrollment vith no more f diagnosis refers t tablished with cor	codes L10.2 [PF] or L ured between Januar s at index t ± 1-year pre- and po than 1 exclusionary o to diagnosis of a medical co mplete confidence from hist	y 2019 and Dece ost-index date diagnosis ^a for PF ndition reached by a p fory, examination or te	mber 2021 (firs for 1-year after process of elimination esting.	st considered their 2 nd dia n, when the cond	index date) gnoses
 ≥2 claims with the 2 with the 2 Patients a Continuo Patients was a continuo Patients was a continuo be estimated by a continuo be estimated by a contract of the continuo be estimated by a contract of the continuo be estimated by a contract of the context of the context	with PF (ICD of L st claim captu ged ≥18 years us enrollment vith no more f diagnosis refers t tablished with cor Litcomes characteristics	codes L10.2 [PF] or L ured between Januar s at index t ± 1-year pre- and po than 1 exclusionary o to diagnosis of a medical co mplete confidence from hist	y 2019 and Dece ost-index date diagnosis ^a for PF ndition reached by a p fory, examination or te CCI assessed dur	mber 2021 (firs for 1-year after process of elimination esting.	st considered their 2 nd dia n, when the cond	index date) gnoses
 ≥2 claims with the 2 with the 2 Patients a Continuo Patients was a continuo Patients was a continuo be estimated by a continuo be estimated by a contract of the continuo be estimated by a contract of the continuo be estimated by a contract of the context of the context	with PF (ICD of L st claim captu ged ≥18 years us enrollment vith no more f diagnosis refers t tablished with cor Litcomes characteristics	codes L10.2 [PF] or L ured between Januar s at index t ± 1-year pre- and po than 1 exclusionary o to diagnosis of a medical co mplete confidence from hist	y 2019 and Dece ost-index date diagnosis ^a for PF ndition reached by a p fory, examination or te CCI assessed dur	mber 2021 (firs for 1-year after process of elimination esting.	st considered their 2 nd dia n, when the cond	index date) gnoses
 ≥2 claims with the 2 with the 2 Patients a Continuo Patients was a continuo Patients was a co	with PF (ICD of L st claim captu ged ≥18 years us enrollment vith no more f diagnosis refers t tablished with cor LICOMES characteristics ents evaluate	codes L10.2 [PF] or L ured between Januar s at index t ± 1-year pre- and po than 1 exclusionary o to diagnosis of a medical co mplete confidence from hist s evaluated at index; ed during 1-year post	y 2019 and Dece ost-index date diagnosis ^a for PF ndition reached by a p fory, examination or te CCI assessed dur	mber 2021 (firs for 1-year after process of elimination esting.	st considered their 2 nd dia n, when the cond	index date) gnoses
 ≥2 claims with the 2 with the 2 Patients a Continuo Patients was a continuo Patients was a co	with PF (ICD of L st claim captu ged ≥18 years us enrollment vith no more f diagnosis refers t tablished with cor Litcomes characteristics	codes L10.2 [PF] or L ured between Januar s at index t ± 1-year pre- and po than 1 exclusionary o to diagnosis of a medical co mplete confidence from hist s evaluated at index; ed during 1-year post	y 2019 and Dece ost-index date diagnosis ^a for PF ndition reached by a p fory, examination or te CCI assessed dur	mber 2021 (firs for 1-year after process of elimination esting.	st considered their 2 nd dia n, when the cond	index date) gnoses

Results

Study population

Overall, 345 patients met the inclusion criteria and were included in the analysis (Figure 2).

Figure 2. Patient selection

	41,572	Any diagnosis of PF or pemphigus (L10.2 or
Any diagnosis of PF between 01 January 2019 O and 31 December 2021	17,906	L10.9) ≥2 PF diagnosis claims ≥30–≤365 days apart with ≥2
Excluding patients with ≥2	1,676	claims for L10.2 in 1-year post-index
exclusionary diagnoses for PF _O	1,468	Patients aged ≥18 years as of index date
Continuous enrollment ± 1-year pre- and post-index	1,432 1,023	index date
date	678	- · - ► O Patients with open claims
Patients with closed claims (cohort of interest) PF, pemphigus foliaceus.	345	

Real-world treatment patterns in adults with pemphigus foliaceus in the United States

Results

Baseline patient demographics and characteristics

- Mean (SD) age of patients was 57.0 (16.0) years (Table 1).
- PF was predominant in women (56.5%) in general, and was more common in the 41 to 65 years age group across males and females.
- The mean (SD) Charlson Comorbidity Index (CCI) was 1.2 (2.0).
- The most commonly observed comorbidities were hypertension (36.5%), atopic dermatitis (33.6%), and obesity (22.0%).

Table 1. Baseline patient demographics and characteristics


	N=345
Age, years, mean (SD)	57 (16.0)
Male, n (%)	150 (43.5)
Aged 18–40 years	21 (6.1)
Aged 41–65 years	81 (23.5)
Aged 65+ years	48 (13.9)
Female, n (%)	195 (56.5)
Aged 18–40 years	34 (9.9)
Aged 41–65 years	111 (32.2)
Aged 65+ years	50 (14.5)
Race, n (%)	
Caucasian	141 (40.9)
African American	47 (13.6)
Asian	16 (4.6)
Other/unknown	141 (40.9)
Insurance, n (%)	
Commercial	219 (63.5)
Self insured	107 (31.0)
Medicare/Medicare advantage	99 (28.7)
Medicaid	90 (26.1)
Dual eligible/other/unknown	34 (9.8)
Charlson Comorbidity Index, mean (SD)	1.2 (2.0)
0, n (%)	186 (53.9)
1–2, n (%)	105 (30.4)
3–4, n (%)	37 (10.7)
≥5 <i>,</i> n (%)	17 (4.9)
Comorbidities, n (%)	
Hypertension	126 (36.5)
Atopic dermatitis	116 (33.6)
Obesity	76 (22.0)
Diabetes without chronic complication	61 (17.7)
CPD	50 (14.5)
Anxiety	32 (9.3)
Depression	32 (9.3)
Diabetes with chronic complication	26 (7.5)
CPD, chronic pulmonary disease; SD, standard deviation.	

CPD, chronic pulmonary disease; SD, standard deviation

Overall PF treatment utilization in 1-year post-index

- Almost all patients identified with PF (n=322; 93.3%) were treated in the 1-year post-index.
- Of 345 patients identified, 206 were newly diagnosed with PF and 139 had previous diagnosis of PF.
- The proportion of patients treated for PF during the 1-year post-index were similar across newly and previously diagnosed patients (Figure 3).

Figure 3. Number of treated patients with PF



- (Figure 4).

Figure 4. Proportion of patients using PF treatment at least once during 1-year post-index

	90
(%	80
its (70
of patients	60
f pa	50
n of	40
rtio	30
Proportion	20
Pro	10
	C

Methylprednisolone

Ar	-
ut	
M	
or	
Fu	
ра	
ide	


PF, pemphigus foliaceus.

Overall treatment patterns during 1-year post-index

The most common PF treatment utilized 1-year post-index was corticosteroids (CS; n=293; 84.9%), followed by IS, broad-spectrum antibiotics, and rituximab

• Among 293 patients who used CS at least once, the majority were treated with topical CS (69.0%), followed by oral CS (54.8%; Figure 4).


• Almost 75.0% of patients required combination therapies for PF during the 1year post-index period, with 49.6% using 3 or more treatment classes (Figure 5).



Oral CS: Prednisolone, Prednisone. Topical CS: Triamcinolone, Flucocinonide, Clobestal, Betamethasone, Hydrocortisone, Dexamethasone. IS: Methotrexate, Azathioprine, Mycophenolate. BS antibiotics: Doxycycline, Dapsone; IV CS: Prednisone, Prednisolone, Dexamethasone,

^aPercentages have been calculated against total patients in cohort. BS, broad-spectrum; CS, corticosteroids; IS, immunosuppressants; IV, intravenous; IVIg, intravenous immunoglobulin; PLEX, plasma exchange; SCIg, subcutaneous immunoglobulin.

Figure 5. Proportion of patients with PF by number of treatment classes exposed to in 1-year post-index (N=345)



Conclusions

- mong 345 patients with PF, CS were the most frequently tilized treatments during 1-year post-index.
- **lost patients used combination treatments as well as regular** ral CS, suggesting potential high treatment burden.
- urther research should assess the impact of these treatment atterns on clinical, humanistic and economic burden in PF to lentify any areas of potential unmet need.

Table 2. Oral CS usage during 1-year post-index

	N=345	
Patients prescribed oral CS, n (%)	189 (54.8)	
Average time on oral CS treatment, days	130.2	
Patients with regular oral CS usage ^{a,b,c} , n (%)	128 (67.7)	
Dosage breakdown over oral CS usage period ^{a,c} , n (%)		
<5 mg	7 (3.7)	
≥5–10 mg	14 (7.4)	
≥10–15 mg	29 (15.3)	
≥15–40 mg	101 (53.4)	
≥40 mg	36 (19.0)	
N/A ^d	2 (1.1)	
All data points are reported among patients who have been prescribed at least one dose of oral CS. Regular oral CS usage was defined as ≥20 mg daily Prednisone equivalent for 14 consecutive days at any point. Percentages were calculated against all patients who were prescribed oral CS (n=189). Two patients did not have any claims for oral CS in the pharmacy table. These patients were not considered in the Oral CS dosing analysis. CS, corticosteroids; mg, milligram; N/A, not available.		

Rituximab utilization during 1-year post-index

- (64.7%).

Table 3. First instance of rituximab usage during 1-year post-index

	N=345
Patients prescribed rituximab ^a , n (%)	77 (22.3)
Monotherapy ^b	6 (7.8)
Combination ^b	
Rituximab+oral CS ^b	34 (44.2)
0–10 mg/day ^c	4 (11.8)
10–20 mg/day ^c	6 (17.6)
>20 mg/day ^c	22 (64.7)
Unknown ^c	2 (5.9)
Rituximab+IV CS ^b	28 (36.4)
Rituximab+other ^b	8 (10.4)
^a Patients on rituximab may be underrepresented due the dosing schedule for PF and the limited follow-up (1-year post-index) in this study. Studies with longer follow-up are needed to confirm these results. ^a Percentages shown were calculated against total patients prescribed rituximab (n=77). 1.3% of patients on rituximab (n=1) had too short of exposure to be considered a complete line of therapy and were excluded from subsequent subgroup analyses. ^a Percentages shown were calculated against total patients using rituximab + oral CS (n=34).	

Limitations

As the study was based on one US claims database, the results full US or global landscape of patients with PF.

CS, corticosteroids; IV, intravenous

 Being a retrospective study, parameters such as disease activity and effectiveness could not be analyzed.

Oral CS utilization during 1-year post-index

• Among the 189 patients who utilized oral CS at least once during 1-year post-index, more than half had regular usage of oral CS (n=128/189; 67.7%, >20 mg/day on average for 14 consecutive days, **Table 2**).

CS, corticosteroids; mg, milligram; N/A, not available.

Nearly half of patients treated with rituximab in the 1-year post-index had their 1st instance of rituximab treatment post-index in combination with oral CS (n=34/77; 44.2%; **Table 3**).

Patients using rituximab concomitantly with oral CS commonly used >20 mg/day of oral CS, with approximately two-thirds using >20 mg/day as their initial dose

may not be representative of the

Funding: This study was funded by argenx BVBA (Ghent, Belgium). Disclosures: Cécile Blein, Francesca Barion, Olga Ostrovskaya, and Glenn Phillips are employees of argenx. Tharun Balaji Suthagar, Vasanth Radhakrishnan, Rucha Kulkarni, and Amit Goyal are

employees of ZS Associates. Acknowledgements: The authors thank Mai Sato, PhD (ZS Associates) and Kalpana Tilekar, PhD (SIRO Clinpharm Pvt. Ltd.) for medical writing support, and Sandeep Chavan (SIRO Clinpharm Pvt. Ltd.) for layout design support for the development of the poster.

References: 1. Farsi M, et al., Dermatol Online J. 2023;29(5).

2. About Pemphigus foliaceus. Genetic and Rare Diseases (GARD) Information Center website. https://rarediseases.info.nih.gov/diseases/7354/pemphigus-foliaceus

- 3. Lepe K et al. Pemphigus Foliaceus. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. https://www.ncbi.nlm.nih.gov/books/NBK499829/
- 4. Carver C, et al., Front Immunol. 2023;14:1267668 5. Altman M, et al., Am J Clin Dermatol. 2020;21(6):765-782.





Presented at ISPOR 2024, 5-8 May 2024, Atlanta, GA, USA